Reticulocyte Count (Absolute)

No risk curve catalogued yet.

What studies found when this marker was changed

They describe what happened in those study groups, not a recommendation. See all catalogued interventions.

Measured changes in Absolute, study by study

1 effect with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Study results in the groups studied, not predictions for a person.

Each row is one study: what was changed, the effect it reported on this marker, and the source.
Type	Intervention	Reported effect	Evidence	Source
pharmacologic	Oral pyruvate kinase activator therapy for >=2 weeks in adults with sickle cell disease (mostly HbSS on hydroxyurea)	Absolute reticulocyte count fell (MD -62.8 × 10³/µL; 95% CI -92.1 to -33.5) with PK activator therapy	meta-analysis	Guimaraes Barbosa Coelho H, et al. Hemoglobin. 2026. Pyruvate Kinase Activators…

Sources

See the catalogue entry in the research dashboard.